This study focuses on patients with End Stage Kidney Disease who are receiving chronic dialysis therapy. The research examines the effects of patiromer, a medication that binds to potassium in the body, compared to placebo. The purpose is to determine if this treatment allows patients to reduce or eliminate their dietary restrictions on potassium-rich foods without increasing the risk of having high potassium levels in their blood.

The medication being tested, Veltassa, comes as a powder that is mixed with liquid and taken by mouth. Patients will receive either Veltassa or placebo for three months while continuing their regular dialysis treatment. During this time, doctors will monitor the amount of potassium in patients’ blood and assess whether they can safely include more potassium-containing foods in their diet.

The study will track several health factors, including changes in blood potassium levels, quality of life, and whether patients need additional treatments to manage their potassium levels. The research will also monitor if patients can better tolerate certain heart and blood pressure medications that are typically challenging to use in dialysis patients due to their effects on potassium levels.